NSCLC患者血浆p16和MGMT基因甲基化检测及临床意义

Detection and significance of promoter hypermethylation of p16 gene and MGMT gene in plasma from non-small cell lung cancer patients

目的:检测非小细胞肺癌(non-small cell lung cancer,NSCLC)患者外周血血浆中p16基因、O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)基因启动子的甲基化状态,探讨p16、MGMT基因启动子的异常甲基化在NSCLC筛查及早期诊断中的意义。方法:利用巢式甲基化特异性聚合酶链反应法检测NSCLC患者外周血血浆p16、MGMT基因启动子的甲基化状态。结果:65例NSCLC血浆样品中分别发现19例(29.23%)p16基因启动子异常甲基化和16例(24.62%)MGMT基因启动子异常甲基化,45例正常对照血浆组未检测到p16、MGMT基因启动子的异常甲基化(P<0.05),血浆中两基因甲基化检出率与NSCLC的分型及临床分期无明显相关性(P>0.05)。结论:利用巢式甲基化特异性PCR法检测外周血血浆中p16、MGMT基因启动子的甲基化,可为NSCLC的筛查、早期诊断及预后判断提供有价值的信息。

Objective：To detect the aberrant methylation in the promoter of p16 and O^6-methylguanine DNA methyhransferase （MGMT） gene in peripheral plasma from non-small cell lung cancer （NSCLC） patients and to evaluate the clinical significance in the screening and early diagnosis of NSCLC. nethods-A nested methylation-specific PCR （nMSP） was performed for the detection of pro- moter hypermethylation of p16 gene and MGMT gene in plasma from 65 NSCLC patients. Results. Of the 65 plasma samples ,p16 gene promoter hypermethylation was detected in 19 patients （29.23%） and MGMT gene promoter hypermethylation was found in 16 patients （ 24.62% ）. However, promoter hypermethylation in p16 gene and MGMT gene was not found in plasma samples from the normal controis （ P 〈 0.05 ）. The hypermethylation detection rate in plasma of the two genes did not significantly correlate with the pathological classification and clinical staging of NSCLC i P 〉 0.05 ）. Conclusion ： Detection of the aberrant methylation in the promoter ofp16 gene and MGMT gene in plasma from NSCLC patients by nMSP method might provide valuable information for the screening, early diagnosis, and prediction of prognosis of NSCLC.